Early treatment of Biogen's Spinraza leads to improvement in motor function
undefined undefined/iStock via Getty Images


New data found that infants with spinal muscular atrophy ("SMA") treated in the presymptomatic phase with Biogen's (NASDAQ:BIIB) Spinraza (nusinersen) for a median of 4.9 years led to progressive gains in motor function.
Also, after 11 months of additional follow-up since a 2020 interim analysis, all children who were able to walk alone continued to be able to do so.

Biogen (BIIB) also said it will discuss the design of its phase 3 ASCEND study examining higher dose Spinraza in later-onset, non-ambulatory SMA patients previously treated with Roche's (OTCQX:RHHBY) Genentech unit's Evrysdi
(risdiplam) at the current Muscular Dystrophy Association Clinical & Scientific Conference
At the same conference, the company will present baseline characteristics from the RESPOND study evaluating the efficacy and safety of Spinraza in infants and toddlers following treatment with Novartis' (NYSE:NVS) Zolgensma (onasemnogene abeparvovec).
Read why Seeking Alpha contributor William Meyers says Biogen (BIIB) is a buy.